glp-1 therapy for diabetes Agonists Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Injections for Medical Weight

Results Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria

doi:10.1249/JSR.0b013e31825dabb8 9

Individual weight loss results may vary

Results from studies indicate that ghrelin also promotes lipid retention in adipocytes, which seems paradoxical given this hormones role as a hunger hormone, as during starvation lipids need to be released from stores and catabolised for ATP production, although it has also been argued that ghrelin protects fat stores from being utilised so that they can be used for ATP production during prolonged starvation

Drug classes to be on the lookout for are outlined in Table 2 , and include several major buckets: Incretins Plus : these assets often add additional agonism to the classic GLP-1 or GLP-1/GIP drugs

Anti-inflammation and Anti-oxidation: the Key to unlocking the Cardiovascular potential of SGLT2 inhibitors and GLP1 receptor agonists